ReviewFrontiers in immunology2026
Divergent immunometabolic reprogramming in psoriasis and atopic dermatitis: a tale of two inflammatory skin diseases.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis (PSO) and atopic dermatitis (AD) are the two most common chronic inflammatory skin diseases in clinical practice. For a long time, they have been classified in pathological immunology under the opposing model of "Th17/IL-17 vs. Th2/IL-4-IL-13." However, over the past decade, with the rise of immunometabolism, our understanding of chronic inflammatory diseases has undergone a significant shift. Metabolic pathways in immune cells are no longer viewed merely as auxiliary systems providing energy, but rather as core regulatory networks that determine cellular differentiation and effector functions. In psoriasis, hallmark features include upregulation of glycolysis, activation of hypoxia-inducible factor-1α (HIF-1α), abnormalities in cholesterol metabolism, and Warburg-like metabolism in keratinocytes. In AD, defects in epidermal ceramide synthesis, impaired essential fatty acid metabolism, disruption of the tryptophan-kynurenine pathway, and abnormal aromatics receptor (AhR) signaling constitute its unique metabolic profile. This article systematically reviews the distinct pathways of metabolic reprogramming in keratinocytes and immune cells in psoriasis and AD, and summarizes the mechanisms of action of key molecules such as mTOR and AMPK. Furthermore, it explores the differential therapeutic potential of metabolism-targeted drugs, including metformin, statins, PPARγ agonists, and AhR modulators. Furthermore, the expression of common regulatory factors such as HIF-1α, PPARγ, and SREBP exhibits opposite trends in the two diseases. Finally, the article discusses the differential therapeutic potential of these metabolite-targeted drugs. This paper compares psoriasis and AD within a unified metabolic immunology framework, aiming to elucidate how these two diseases evolve from similar inflammatory responses into conditions with distinctly different clinical manifestations, and to provide a new theoretical foundation for future metabolism-based personalized therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.